4.7 Article

Structural basis of Keap1 interactions with Nrf2

Journal

FREE RADICAL BIOLOGY AND MEDICINE
Volume 88, Issue -, Pages 101-107

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.freeradbiomed.2015.05.034

Keywords

Keap1; Nrf2; BTB; Kelch; Cullin; Ubiquitin; Free radicals

Funding

  1. AbbVie [1097737]
  2. Bayer
  3. Boehringer Ingelheim
  4. Genome Canada through Ontario Genomics Institute Grant [OGI-055]
  5. GlaxoSmithKline
  6. Janssen
  7. Lilly Canada
  8. Novartis Research Foundation
  9. Ontario Ministry of Economic Development and Innovation
  10. Pfizer
  11. Takeda
  12. Wellcome Trust Grant [092809/Z/10/Z]
  13. Wellcome Trust [092809/Z/10/Z] Funding Source: Wellcome Trust

Ask authors/readers for more resources

Keap1 is a highly redox-sensitive member of the BTB-Kelch family that assembles with the Cul3 protein to form a Cullin-RING E3 ligase complex for the degradation of Nrf2. Oxidative stress disables Keap1, allowing Nrf2 protein levels to accumulate for the transactivation of critical stress response genes. Consequently, the Keap1-Nrf2 system is extensively pursued for the development of protein-protein interaction inhibitors that will stabilize Nrf2 for therapeutic effect in conditions of neurodegeneration, inflammation, and cancer. Here we review current progress toward the structure determination of Keap1 and its protein complexes with Cul3, Nrf2 substrate, and small-molecule antagonists. Together the available structures establish a rational three-dimensional model to explain the two-site binding of Nrf2 as well as its efficient ubiquitination. (C) 2015 The Authors. Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available